



Curriculum vitae

Personal profile

Name: Pagani Santoro

First names: Olivia

Professional address

Institute of Oncology of Southern Switzerland
Ospedale Beata Vergine
6850 Mendrisio
Tel. +41 91 - 811 3467
Fax +41 91 - 811 3027

e-mail : olivia.pagani@ibcs.org

Place and date of birth: Como (Italy)
4.5.1958

Nationality: Swiss and Italian

Short sketch

Main current research interest: breast cancer and genetic counselling, on which the latest publications have been focused.

Additional publications on phase I/II studies of a number of novel agents and therapies, on patient-doctor communication and on home-care services in the terminally ill patient.

Principal investigator of past and current trials conducted by the International Breast Cancer Study Group (IBCSG) and by SAKK (Swiss Institute for Applied Cancer).

Member of the European Society for Medical Oncology (ESMO) and of the SAKK Network for Cancer Predisposition Testing and Counselling.

Prizes and awards:

Education

1977: Graduated from High School

1985: Degree of Medicine

(State University of Milan, Italy)

Experimental Thesis on Monoclonal Antibodies in ovarian cancer

1988: Speciality in Oncology
(State University of Milan, Italy)
Thesis on laser conization

**Professional experience
and current activities**

1.1986 - 11.1987 Resident, Dept. of Diagnostic Oncology and
Outpatient Clinic
Istituto Nazionale Tumori, Milan, Italy

12.1987 - 7.1989 Fellowship, Dept. of Diagnostic Oncology and
Outpatient Clinic
Istituto Nazionale Tumori, Milan, Italy

8.1989 - 6.1992 Assistant physician, Dept. of Medical Oncology
Ospedale S.Giovanni, Bellinzona, Switzerland

4.1994 - 9.1994 Resident, Cancer Research Unit
Prof. H. Calvert
Newcastle upon Tyne (GB)

Current Position

Since July 1992 Staff Oncologist, Dept. of Medical Oncology
Institute of Oncology of Southern Switzerland (IOSI)

Since April 2005 Breast Cancer Consultant
Breast Unit of the Institute of Oncology of Southern Switzerland

Since June 2005 Co-president of the breast cancer project group of the
Swiss Institute for Applied Cancer Research (SAKK)

Miscellaneous:

Publication:

A. Diotti, O. Santoro, L. Mantovani, M. Regazzoni, R. Fontanelli, F. Ravagnani, S. Miotti, S. Menard,
M.I. Colnaghi

**A double determinant radio-immunoassay MOv2-MOv8 for monitoring ovarian carcinomas:
definition of the methodology**

The International Journal of Biological Markers 2: 161- 168, 1987

O. Santoro, G. Bandieramente, E. Melloni, R. Marchesini, F. Zunino, P. Lepera, G. De Palo
**Photodynamic therapy by topical meso-Tetraphenylporphinesulfonate Tetrasodium Salt
administration in superficial basal cell carcinomas.**

Cancer Res 50: 4501-4503, 1990

M. Marzola, M. Zucchetti, N. Colombo, C. Sessa, O. Pagani, M. D'Incalci, F. Cavalli, C. Mangioni
Low-dose oral etoposide in epithelial cancer of the ovary.
Ann Oncol 4: 517-519, 1993

C. Sessa, M. Zucchetti, V. Torri, O. Pagani, M. D'Incalci, D. Gentili, G. Martinelli, J. deJong, M. Alerci, F. Cavalli
Chronic oral etoposide in small cell lung cancer: clinical and pharmacokinetic results.
Ann Oncol 4: 553-558, 1993

D.C. Betticher, M.F. Fey, A. von Rohr, A. Tobler, H. Jenzer, A. Gratwohl, A. Lohri, P. Pugin, U. Hess, O. Pagani, G. Zulian, T. Cerny
High incidence of infections after 2-chlorodeoxyadenosine (2-CDA) therapy in patients with malignant lymphomas and chronic and acute leukaemia.
Ann Oncol 5: 57-64, 1994

C. Sessa, O. Pagani, M.G.Zurlo, J. de Jong, C. Hofmann, M. Lassus, P. Marrari, M. Strolin Benedetti, F. Cavalli
Phase I study of the novel distamycin derivative tallimustine (FCE 24517).
Ann Oncol 5: 901-7, 1994

M. Tomamichel, C. Sessa, S. Herzig, J. de Jong, O. Pagani, Y. Willems & F. Cavalli
Informed consent for phase I studies: evaluation of quantity and quality of information provided to patients
Ann Oncol 6: 363-369, 1995

C. Sessa, O. Pagani, G. Parma, A. Goldhirsch, F. Cavalli
Dose-Finding Study of Paclitaxel and Cyclophosphamide in Patients with Advanced Breast Cancer
Seminars Oncol 22 (Suppl 6): 112-117, 1995

Sessa C, Zucchetti M, Cerny T, Pagani O, Cavalli F, De Fusco M, De Jong J, Gentili D, McDaniel C, Prins C, et al.
Phase I clinical and pharmacokinetic study of oral etoposide phosphate.
J Clin Oncol. 13(1):200-9, 1995

C. Sessa, J. de Jong, M. D'Incalci, S. Hatty, O. Pagani, F. Cavalli
Phase I study of the Antipurine Antifolate Lometrexol (DDATHF) with Folinic Acid Rescue
Clinical Cancer Res 2: 1123-1127, 1996

P. Saletti, O. Pagani, C. Sessa, A. Goldhirsch
Two cases of neurotoxicity possibly related to 5-fluorouracil and FA administration
Ann Oncol 7: 213-214, 1996

O. Pagani-Santoro, A. Goldhirsch
Breast Cancer Biology: possible clinical applications.
Carcinoma mammario. Diagnosi e terapia. Breast Cancer. Diagnosis and therapy. Ed. G. Robustelli della Cuna, G. Bonadonna. Edizioni Medico scientifiche, Chptr 1, p 11-40, 1992

P. Saletti, O. Pagani, F. Cavalli

Occurrence of second neoplasia (non-Hodgkin's Lymphoma) in a patient with Hairy cell Leukaemia (HCL) treated with alfa 2a Interferon (IFN) Bulletin Suisse du Cancer N° 4 (Dec 1995): 156

O. Pagani, C. Sessa, F. Cavalli

Platinum dose-intensity in solid tumours: pharmacological and clinical perspectives Bulletin du Cancer 82 (suppl 1): 16s-23s, 1995

O. Pagani, M. Zucchetti, C. Sessa, J. de Jong, M. D'Incalci, M. De Fusco, A. Kaeser-Frölich, A. Hanauske, F. Cavalli

Clinical and pharmacokinetic study of oral NK611, a new podophyllotoxin derivative. Cancer Chemother Pharmacol 38: 541-547, 1996

O. Pagani, P. Rey, A. Goldhirsch

Sostituzione ormonale per la menopausa: prevenzione senza rischi? Tribuna Medica Ticinese 61: 353-357, 1996

Sessa C, Roggero E, Pampallona S, Regazzoni S, Ghielmini M, Lang M, Marx B, Neuenschwander H, Pagani O, Vasilievic V, Cavalli F.

The last 3 months of life of cancer patients: medical aspects and role of home-care services in southern Switzerland.

Support Care Cancer.4(3):180-5, 1996

O. Pagani, C. Sessa, G. Martinelli, T. Cerny, J. de Jong, A: Goldhirsch, M. Zimatore & F. Cavalli

Dose- finding study of paclitaxel and cyclophosphamide in advanced breast cancer Ann Oncol 8: 655-661, 1997

C. Sessa, O. Pagani, G. Martinelli, T. Cerny, J. de Jong, A: Goldhirsch, M. Zimatore & F. Cavalli

Dose- finding study of paclitaxel and cyclophosphamide in women with advanced breast cancer Seminars in Oncology, Vol 24: S17-52-S17-57, 1997

Goldhirsch A, Gelber RD, Castiglione M, O'Neill A, Thurlimann B, Rudenstam CM, Lindtner J, Collins J, Forbes J, Crivellari D, Coates A, Cavalli F, Simoncini E, Fey MF, Pagani O, Price K, Senn HJ.

Menstrual cycle and timing of breast surgery in premenopausal node-positive breast cancer: results of the International Breast Cancer Study Group (IBCSG) Trial VI.

Ann Oncol.8(8):751-6, 1997

C. Sessa, C. Minoia, A. Ronchi, M. Zucchetti, M. D'Incalci, J. Bauer, M. Borner, J. De Jong, O. Pagani, J. Renard, T. Vandenbulcke, C. Weil and F. Cavalli

Phase I clinical and pharmacokinetic study of the oral platinum analogue (JM216) given daily for 14 days

Ann of Oncology 9: 1315-1322, 1998

O. Pagani, A. O'Neill, M. Castiglione, R.D. Gelber, A. Goldhirsch, C-M. Rudenstam, J. Lindtner, J. Collins, D. Crivellari, A. Coates, F. Cavalli, B. Thürlimann, E. Simoncini, M. Fey, K. Price, H-J. Senn

Prognostic impact of amenorrhea after adjuvant chemotherapy in premenopausal breast cancer patients with axillary node involvement: results of the International Breast Cancer Study Group (IBCSG) Trial VI

Eur J Cancer 34 (5): 632-640, 1998

Goedhals L, Heron JF, Kleisbauer JP, Pagani O, Sessa C.

Control of delayed nausea and vomiting with granisetron plus dexamethasone or dexamethasone alone in patients receiving highly emetogenic chemotherapy: a double-blind, placebo-controlled, comparative study.

Ann Oncol. 9(6):661-6, 1998

Colleoni M, Coates A, Pagani O, Goldhirsch A.

Combined chemo-endocrine adjuvant therapy for patients with operable breast cancer: still a question?

Cancer Treat Rev. 24(1):15-26, 1998

M.M. Borner, M. Castiglione, M. Bacchi, W. Weber, R. Hermann, M.F. Fey, O. Pagani, S. Leyvraz, R. Morant, B. Pestalozzi, S. Hanselmann, A Goldhirsch

The impact of adding low-dose leucovorin to monthly 5-fluorouracil in advanced colorectal carcinoma: results of a Phase III trial

Ann Oncol 9:535-541, 1998

R. Stupp, J. Bauer, O. Pagani, B. Gerard, T. Cerny, C. Sessa, G. Bastian, M. Sarkany, J. Schlapfer, B. Giroux, S. Leyvraz

Ventricular arrhythmia and torsade de pointe: dose limiting toxicities of the MDR-modulator S9788 in a phase I trial.

Ann Oncol 9:1233-1242, 1998

Pagani O.

Taxoids in combination with epirubicin: the search for improved outcomes in breast cancer.

Semin Oncol. 25(5 Suppl 12):23-6, 1998

O. Pagani, C. Sessa, G. Martinelli, D. Crivellari, A. Buonadonna, B. Thürlimann, D. Hess, M. Borner, J. Bauer, G. Zampino, M. Zimatore, R. Graffeo, A. Riva, A. Goldhirsch.

Dose finding study of epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer.

Ann Oncol. 10(5):539-45, 1999

Ghielmini M, Pagani O, de Jong J, Pampallona S, Conti A, Maestroni G, Sessa C, Cavalli F.

Double-blind randomized study on the myeloprotective effect of melatonin in combination with carboplatin and etoposide in advanced lung cancer.

Br J Cancer. 80 (7):1058-61, 1999

Pagani O, Sessa C, Nole F, Crivellari D, Lombardi D, Thurlimann B, Hess D, Borner M, Bauer J, Martinelli G, Graffeo R, Zucchetti M, D'Incalci M, Goldhirsch A.

Epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer: a multicentric phase I-II study.

Ann Oncol. 11(8):985-91, 2000

Roth AD, Maibach R, Martinelli G, Fazio N, Aapro MS, Pagani O, Morant R, Borner MM, Herrmann R, Honegger H, Cavalli F, Alberto P, Castiglione M, Goldhirsch A.

Docetaxel (Taxotere)-cisplatin (TC): an effective drug combination in gastric carcinoma. Swiss Group for Clinical Cancer Research (SAKK), and the European Institute of Oncology (EIO).

Ann Oncol. 11(3):301-6, 2000

Tomamichel M, Jaime H, Degrate A, de Jong J, Pagani O, Cavalli F, Sessa C.
Proposing phase I studies: patients', relatives', nurses' and specialists' perceptions.
Ann Oncol. 11(3):289-94, 2000

Graffeo R, Pagani O, Crivelli M, Zappa F, Borella P, Reiner M, Goldhirsch A.
Parathyroid hormone-related protein in metastatic breast cancer induced hypercalcemia: a case report.
Ann Oncol. 11(1):97-100, 2000

Sessa C, Pagani O.
Docetaxel and epirubicin in advanced breast cancer.
Oncologist. 6 (Suppl 3):13-6, 2001

Crivellari D, Pagani O, Veronesi A, Lombardi D, Nole F, Thurlimann B, Hess D, Borner M, Bauer J, Martinelli G, Graffeo R, Sessa C, Goldhirsch A.
High incidence of central nervous system involvement in patients with metastatic or locally advanced breast cancer treated with epirubicin and docetaxel.
Ann Oncol. 12(3):353-6, 2001

Trudeau M, Pagani O.
Epirubicin in combination with the taxanes.
Semin Oncol 28 (4 Suppl 12):41-50, 2001

T. De Pas, G. Curigliano, G. Masci, C. Catania, A. Comandone, C. Boni, A. Tucci, O. Pagani, E. Marrocco & F. de Braud on behalf of the Italian Sarcoma Group
Phase I study of twelve-day prolonged infusion of high-dose ifosfamide and doxorubicin as first-line chemotherapy in adult patients with advanced soft tissue sarcomas
Ann Oncol 13: 161-166, 2002

C. Sessa, K. Weigang-Köhler, O. Pagani, G. Greim, O. Mora, T. De Pas, M. Burgess, I. Weimer, R. Johnson
Phase I and pharmacological studies of the cryptophycin analogue LY355703 administered on a single intermittent or weekly schedule
Eur J Cancer 38: 2388-96, 2002

Pichert G, Bolliger B, Buser K, Pagani O
Evidence-based management options for women at increased breast/ovarian cancer risk
Ann Oncol 14: 9-19, 2003

Thurlimann B, Hess D, Koberle D, Senn I, Ballabeni P, Pagani O, Perey L, Aebi S, Rochlitz C, Goldhirsch A.
Anastrozole ('Arimidex') versus Tamoxifen as First-line Therapy in Postmenopausal Women with Advanced Breast Cancer: Results of the Double-blind Cross-over SAKK trial 21/95 - a sub-study of the TARGET (Tamoxifen or 'Arimidex' Randomized Group Efficacy and Tolerability) Trial.
Breast Cancer Res Treat. 85 (3):247-54, 2004

International Breast Cancer Study Group

Writing Committee: O. Pagani, S. Gelber, K. Price, D. Zahrieh, R. Gelber, E. Simoncini, M. Castiglione-Gertsch, A.S. Coates, A Goldhirsch

Toremifene and tamoxifen are equally effective for early-stage breast cancer: first results of International Breast Cancer Study Group Trials 12-93 and 14-93

Ann Oncol 15: 1749-59, 2004

D. Hess, B Thürlimann, O Pagani, S Aebi, D. Rauch, P. Ballabeni, B. Rufener, M. Castiglione-Gertsch, A Goldhirsch

Capecitabine and vinorelbine in elderly patients (≥ 65 years) with metastatic breast cancer: a phase I trial (SAKK 25/99)

Ann Oncol 15: 1760-65, 2004

M Colleoni, D Zahrieh, RD. Gelber, SB. Holmberg, JE. Mattsson, CM Rudenstam, J Lindtner, D Erzen, R Snyder, J Collins, MF. Fey, B Thürlimann, D Crivellari, E Murray, C Mendiola, O Pagani, M Castiglione-Gertsch, AS. Coates, K Price, and A Goldhirsch

Site of Primary Tumor Has a Prognostic Role in Operable Breast Cancer: The International Breast Cancer Study Group Experience.

J Clin Oncol 23:1390-1400, 2005

Colleoni M, Li S, Gelber RD, Coates AS, Castiglione-Gertsch M, Price KN, Lindtner J, Rudenstam CM, Crivellari D, Collins J, Pagani O, Simoncini E, Thurlimann B, Murray E, Forbes J, Erzen D, Holmberg S, Veronesi A, Goldhirsch A.

Timing of CMF chemotherapy in combination with tamoxifen in postmenopausal women with breast cancer: role of endocrine responsiveness of the tumor.

Ann Oncol. 16 (5):716-25, 2005

O. Pagani, C. Sessa, F. Nole, E. Munzone, D. Crivellari, D. Lombardi, B. Thürlimann, D. Hess, R. Graffeo, M. Ruggeri, S. Longhi & A. Goldhirsch

Dose-finding study of weekly docetaxel, anthracyclines plus fluoropyrimidines as first-line treatment in advanced breast cancer

Ann Oncol. 16 (10):1609-17, 2005

BC. Pestalozzi, D. Zahrieh, KN. Price, SB. Holmberg, J. Lindtner, J. Collins, D. Crivellari, MF. Fey, E. Murray, O. Pagani, E. Simoncini, M. Castiglione-Gertsch, RD. Gelber, AS. Coates & A. Goldhirsch
For the International Breast Cancer Study Group

Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG)

Ann of Oncology 17 (6):935-44, 2006

O. Pagani, A. Goldhirsch

Breast cancer in young women: climbing for progress in care and knowledge

Women's Health 2 (5): 717-732, 2006

Conti-Beltraminelli M, Pagani O, Ballerini G, Richetti A, Graffeo R, Ruggeri M, Forni V, Pianca S, Schonholzer C, Mainetti C, Cavalli F, Goldhirsch A.

Henoch-Schonlein purpura (HSP) during treatment with anastrozole.

Ann Oncol. 18 (1):205-7, 2007

Keshaviah A, Dellapasqua S, Rotmensz N, Lindtner J, Crivellari D, Collins J, Colleoni M, Thurlimann B, Mendiola C, Aebi S, Price K, Pagani O, Simoncini E, Castiglione Gertsch M, Gelber R, Coates A, Goldhirsch A.

CA15-3 and alkaline phosphatase as predictors for breast cancer recurrence: a combined analysis of seven International Breast Cancer Study Group trials.

Ann Oncol. 2007 Apr;18(4):701-8

Cardoso F, Winer EP, Cignetti F, Costa A, Fallowfield L, Namer M, Pagani O, Rodenhuis S, Senkus-Konefka, Wardley A

Metastatic breast cancer: recommendations proposal from the European School of Oncology (ESO) – MBC Task Force.

The Breast, 16 (1): 9-10, 2007.

Aebi S, Pagani O.

Treatment of premenopausal women with early breast cancer : old challenges and new opportunities.

Drugs, 67 (10):1393-401, 2007.